Colon cancer continues to be one of the leading causes of cancer-related deaths worldwide, with poor dietary habits ...

Cyclin-dependent kinases (CDKs) are protein kinases involved in critical cellular processes, such as cell cycle or transcription, whose activity requires association with specific cyclin subunits.

Results from DENALI Part 1b show an Objective Response Rate (ORR) of ~35% in response-evaluable, heavily-pretreated patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Across monotherapy ...

Cyclin B3, on the other hand, plays an important role in meiosis, another type of cell division. It is responsible for ensuring that meiotic division takes place correctly and that a healthy egg ...

However, the precise mechanism by which these processes are concertedly gated remains unknown. Our study demonstrates that cyclin-dependent kinase 5 (Cdk5) activity is modulated by light and regulates ...

Colon cancer continues to be one of the leading causes of cancer-related deaths worldwide, with poor dietary habits identified as a major risk factor ...

In two studies, we tested whether the docking site on cyclin B – a type of pocket contributes to the correct sequence of events and, if so, what effects it has. By making targeted changes to ...

Drug addiction is a major therapeutic challenge, as little is known about the changes in neural function that occur during its development. DNA microarray analysis has revealed a new component in ...

"We are excited to outline a clear path for Zentalis to bring azenosertib to patients with Cyclin E1+ PROC,” said Ingmar Bruns, M.D., Chief Medical Officer. “In a patient population with a ...

A "pocket" on the protein cyclin B is responsible for ensuring that the steps of cell division take place in the correct order. Two studies by researchers at the University of Konstanz ...

Sellas Life Sciences has reported the multicentre Phase IIa trial data of a highly selective cyclin-dependent kinase 9 (CDK9) ...

Results from DENALI Part 1b show an Objective Response Rate (ORR) of ~35% in response-evaluable, heavily-pretreated patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Across ...